Ericsson's US Clients Accelerate Purchases In Q1 Ahead of Tariffs, Eyes Solid Q2 Despite Global Uncertainty
The Swedish telecom equipment maker's sales grew 3% year-over-year to 55.0 billion Swedish Krona ($5.15 billion), driven by 20% growth in the Americas market. The revenue beat the consensus of $5.10 billion.
Organic sales were stable, with strong growth in the Americas market offset by declines in other market areas.
Ericsson Accelerates 5G Growth in India with Bharti Airtel Deal
Adjusted gross margin improved to 48.5% from 42.7% Y/Y, driven primarily by improved gross margin in Networks.
Adjusted EBIT margin was 11.3% versus 8.1% Y/Y. Adjusted EBITA margin improved to 12.6% from 9.6% a year ago.
Ericsson reported an EPS of SEK 1.24 ($0.12) versus SEK 0.77 Y/Y. It beat the consensus of $0.09.
Free cash flow before M&A was SEK 2.7 billion in the quarter. As of March 31, 2025, net cash stood at SEK 38.6 billion.
Dividend: The board approved the 2024 proposed dividend of SEK 2.85 per share on March 25. The company will pay the dividend in two installments of SEK 1.43 per share and SEK 1.42 per share.
Outlook: Ericsson expects second-quarter sales growth for Networks and Cloud Software and Services to be similar to the 3-year average seasonality.
Based on its current assessment of announced tariffs, it expects second-quarter adjusted gross margin for networks of 48% % to 50%.
Ericsson remains confident in its strong position in Mobile Networks and expects Enterprise to stabilize in 2025.
Bloomberg's Matthew Bloxham expects Ericsson to tackle global tariff storms better than analysts' expectations via cost-cutting tailwinds, preemptive U.S. inventory restocking, and limited exposure to China-sourced components.
While North America accounted for about 30% of the company's revenue in 2024, Bloomberg cited Ericsson's 2024 annual report as citing the company's diversification of its supply chain. The company is building a factory in Texas to produce 5G equipment for U.S. customers.
Morgan Stanley's Sandeep Deshpande told Bloomberg that Ericsson's U.S. business strength was partially driven by customers 'buying products in anticipation of tariffs.
Price Action: ERIC stock is up 8.66% at $8.09 at the last check on Tuesday.
Read Next:Photo via Shutterstock
Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.
Get the latest stock analysis from Benzinga?
TELEFONAKTIEBOLAGET L M (ERIC): Free Stock Analysis Report
This article Ericsson's US Clients Accelerate Purchases In Q1 Ahead of Tariffs, Eyes Solid Q2 Despite Global Uncertainty originally appeared on Benzinga.com
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Praxis' Epilepsy Treatment Shows Promise With Decreased Seizures
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) stock experienced a volatile trading session on Monday, after the company announced positive topline results from its Phase 2 RADIANT study evaluating vormatrigine in patients with focal onset seizures and generalized epilepsy. The stock initially surged on the news, but then reversed course and is currently trading down approximately 9%. The central nervous system (CNS) disorders-focused company said the topline results from the Phase 2 RADIANT study included data from 37 patients.'These findings build on our earlier clinical data showing a differentiated profile for vormatrigine as a fast-acting, no-titration, once-daily oral drug with no requirement to be taken with food, and a favorable DDI profile, all of which are unseen in ASMs currently in the market or in development,' said Marcio Souza, president and CEO of Praxis. In an investor presentation on the company website, Praxis noted that the trial showed a median seizure reduction of around 56.3%, with 60% of the patients achieving at least a 50% reduction in seizures. This positive outcome has encouraged the company to move forward with a Phase 2/3 trial, even though 23% of patients discontinued the study. 54% of patients achieved at least a 50% seizure reduction threshold in Week 1 and 67% in Week 8. In the last month of the dataset, 22% of the patients experienced a 100% reduction in seizure frequency. The company added that most adverse events were mild to moderate and transient. All severe and serious adverse events (AEs) were recovered and resolved. The investor presentation noted that the investigators had the option to reduce the dose of the background medication to manage AEs; when done (6 patients), no discontinuation was observed. The company said it is on track to complete the pivotal, 12-week POWER1 study in the fourth quarter of 2025 and, based on the results from RADIANT, it expects to initiate the POWER2 study shortly. On Monday, the company reported cash and investments of approximately $447 million and maintains a cash runway into 2028. In July, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for Praxis Precision's relutrigine, a sodium channel functional state modulator for pediatric use for SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs). The EMBOLD cohort 2 pivotal trial is on track for topline results in the first half of 2026, with NDA filing to follow. Praxis has recently initiated the EMERALD study investigating relutrigine broadly in DEEs. Price Action: PRAX stock is trading lower by 9.51% to $48.95 at last check Monday. Read Next:Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Praxis' Epilepsy Treatment Shows Promise With Decreased Seizures originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
Yahoo
16 minutes ago
- Yahoo
LyondellBasell Industries N.V. (LYB): A Bull Case Theory
We came across a bullish thesis on LyondellBasell Industries N.V. on DeepValue Capital's Substack. In this article, we will summarize the bulls' thesis on LYB. LyondellBasell Industries N.V.'s share was trading at $62.88 as of July 28th. LYB's trailing and forward P/E were 21.76 and 16.45 respectively according to Yahoo Finance. A factory worker monitoring a conveyor belt of specialty chemicals being produced. LyondellBasell (LYB), one of the world's largest plastics and chemicals producers, operates at the heart of the hydrocarbon-to-plastics value chain, converting oil and gas derivatives into core building blocks like ethylene and propylene, which are polymerized into polyethylene (PE) and polypropylene (PP). These polyolefins account for over 45% of revenue and drive LYB's earnings power, with profitability highly sensitive to spreads between product prices and feedstock costs. The company's U.S. operations benefit from advantaged ethane-based feedstocks, making LYB the lowest-cost large-cap producer globally. Recent performance has been weighed down by trough-level polyethylene pricing, but signs of a cyclical inflection are emerging as PE and PP prices have posted their first consecutive monthly gains in over a year, operating rates are rising, and inventories are normalizing. Macroeconomic tailwinds, including accelerating China stimulus and a bottoming U.S. PMI, support a potential restocking cycle heading into 2026, positioning LYB as a high-leverage beneficiary. Financial quality remains intact with a 10-year median ROIC above 20%, a near-9% dividend yield, a disciplined 70–80% FCF payout policy, and a strong balance sheet. Management has shifted toward disciplined growth with projects like the Flex‑2 propylene unit and MoReTec recycling facility, while keeping capex modest. Shares have fallen over 40% from 2024 highs, pricing in a prolonged downturn. A return to mid-cycle margins and selective growth could expand FCF margins to 12% and lift fair value toward $274, implying ~394% total returns over five years, with LYB offering a compelling combination of scale, structural cost advantage, and early-cycle upside. Previously we covered a bullish thesis on Eastman Chemical Company (EMN) by Necessary-Damage5658 in November 2024, which highlighted its opportunity to gain market share as export controls favor compliant suppliers. The company's stock price has depreciated approximately by 24% since our coverage because the thesis didn't play out amid weaker demand. DeepValue Capital shares a similar but emphasizes LYB's advantaged feedstocks and early-cycle leverage. LyondellBasell Industries N.V. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 38 hedge fund portfolios held LYB at the end of the first quarter which was 46 in the previous quarter. While we acknowledge the potential of LYB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
19 minutes ago
- Bloomberg
Ether Suddenly On A Tear
Bloomberg ETF IQ TV Shows After years in the shadow of Bitcoin, Ether – a cryptocurrency tied to the Ethereum blockchain — is suddenly on a tear as both retail and institutional traders pile into digital assets. Bloomberg's Isabelle Lee has more on the story. (Source: Bloomberg)
